Dianthus Therapeutics Inc. (87E)
XSTU
Real-time Data
06:00 AM
Day's Range
84.0052 wk Range
28.40Overview - 87E - Dianthus Therapeutics Inc.
Key Statistics
Valuation
Enterprise Value
-49.70M
P/E (Trailing)
‪-20.11‬
PEG Ratio
‪-8.85‬
Price / Book
‪4.03‬
EV / EBITDA
‪0.27‬
Profitability
Operating Margin
‪-8,739.34%‬
Return on Assets
‪-30.57%‬
Return on Equity
‪-32.90%‬
Ownership
Shares Outstanding
54.79M
Price stats
50-Day Avg
‪92.29‬
200-Day Avg
‪68.55‬
Peers - 87E - Dianthus Therapeutics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on XSTU.
- 87EXSTUDianthus Therapeutics Inc.+76.34%52-week change-22.14P/E (Trailing)—Profit Margin
- 37TXSTUForte Biosciences, Inc.+86.11%52-week change-13.91P/E (Trailing)—Profit Margin
- 0QFXSTUModerna Inc.+83.17%52-week change-18.38P/E (Trailing)‪54.83%‬Profit Margin
- 3920XSTUSpyre Therapeutics, Inc.+81.45%52-week change-38.38P/E (Trailing)—Profit Margin
- 0MEXSTUTwist Bioscience Corporation+80.18%52-week change-84.15P/E (Trailing)‪50.72%‬Profit Margin
- 5NRXSTUNanobiotix S.A.+78.42%52-week change—P/E (Trailing)—Profit Margin
- 3O8XSTUOmeros Corp.+77.40%52-week change-323.00P/E (Trailing)—Profit Margin
Profile Summary - 87E - Dianthus Therapeutics Inc.
About
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. The company is centered on complement-targeting science, with a portfolio of monoclonal antibodies and fusion proteins designed to selectively modulate immune pathways…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
